Luciferase Reporter Cell Line - JIMT-1

JIMT-1 is a human breast cancer cell line derived from a pleural metastasis of a patient with invasive ductal carcinoma who had developed resistance to Trastuzumab therapy. This cell line is widely recognized as a clinically relevant model for studying HER2-positive breast cancer characterized by intrinsic or acquired mechanisms of drug resistance. In the field of breast cancer research, it is frequently utilized to investigate tumor biology, therapeutic responses, and mechanisms of drug resistance. In in vitro culture, JIMT-1 cells typically exhibit an epithelial-like morphology, making them highly suitable for experiments involving cell proliferation, migration, invasion, cytotoxicity, and signal transduction pathway analysis. The JIMT-1 Luciferase Reporter Cell Line was genetically engineered from the parental JIMT-1 cell line to stably express a luciferase reporter gene. By stably integrating the reporter gene construct into the cellular genome, these cells generate a luminescent signal upon the addition of an appropriate luciferase substrate, thereby enabling the sensitive and quantitative detection of viable cell numbers or tumor burden.

The JIMT-1 Luciferase Reporter Cell Line is broadly applicable across various fields of cancer research and drug development. In in vitro studies, this cell line is ideally suited for evaluating the anti-proliferative or cytotoxic effects of various candidate compounds, monoclonal antibodies, antibody-drug conjugates (ADCs), immunotherapies, or combination treatment regimens against HER2-positive and Trastuzumab-resistant breast cancer. The luminescent signal serves as a surrogate marker for cell viability, enabling researchers to conduct dose-response studies, calculate drug inhibitory concentrations (IC values), compare the efficacy of different treatment strategies, and perform high-throughput screening of large compound libraries using microplate-based assay formats. Furthermore, this cell line holds significant value for in-depth investigations into the mechanisms of drug resistance. Relevant research encompasses various aspects, including alterations in the HER2 signaling pathway, activation of downstream PI3K/AKT or MAPK pathways, the phenomenon of epithelial-mesenchymal transition (EMT), and dynamic changes in pathways associated with tumor cell survival. In in vivo studies, JIMT-1-Luc cells can be implanted into suitable animal models to establish xenograft or metastatic breast cancer models. Subsequently, these models can be subjected to non-invasive, real-time monitoring using bioluminescence imaging techniques.